Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 3 Carcinoma, Non-Small-Cell Lung 2 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) 1 Neoplasms 1 Neoplasm Metastasis 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Colonic Neoplasms 1

Interventions

Dexamethasone 28 Rituximab 16 pomalidomide 13 Gemcitabine 12 Lenalidomide 11 Cisplatin 11 Bortezomib 11 Paclitaxel 10 Cyclophosphamide 8 Carboplatin 8 carfilzomib 7 selinexor 5 daratumumab 5 Drug Therapy 5 Doxorubicin 5 Cytarabine 5 ibrutinib 4 Vincristine 4 Temozolomide 4 Prednisone 4 Docetaxel 4 Calcium Dobesilate 4 Bevacizumab 4 Aspirin 4 tisagenlecleucel 3 Cetuximab 3 Bendamustine Hydrochloride 3 venetoclax 2 ofatumumab 2 galiximab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recurrence × dostarlimab × Clear all

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡